Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
140 Results for "
Configuration
" in MedChemExpress (MCE) Product Catalog:
Products (140)
140 Results for "Configuration" in MCE Product Catalog:
Cat. No.: HY-B0428D
CAS No.: 130952-46-4
Synonyms: (E/Z)-OKY-046 sodium
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
(E/Z)-Ozagrel sodium [(E/Z)-OKY-046 sodium] is an EZ configuration mixture of Ozagrel sodium (HY-B0428A). Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .
Cat. No.: HY-N12964
CAS No.: 106941-27-9
Target:
Cat. No.: HY-W001294
CAS No.: 109431-87-0
Research Areas:
(R)-(-)-N-Boc-3-pyrrolidinol is a chiral pyrrolidine derivative. After undergoing configuration inversion via the Mitsunobu reaction, (R)-(-)-N-Boc-3-pyrrolidinol can serve as a precursor for the (3S)-aryloxypyrrolidine fragment, which is used to construct key intermediates of FXa inhibitors (such as DX-9065a (HY-10722)) and various chiral drugs. (R)-(-)-N-Boc-3-pyrrolidinol can be applied in studies related to arrhythmia .
Cat. No.: HY-N21584
CAS No.: 132185-42-3
Target:
Cat. No.: HY-N21798
CAS No.: 2614004-95-2
Target:
Cat. No.: HY-P11099
CAS No.: 1254540-73-2
Target:
Research Areas:
Cat. No.: HY-N0120
CAS No.: 65914-17-2
Synonyms: (E/Z)-Piceid
Category:
Stilbenes Polygonaceae Reynoutria japonica Houtt. Phenols Polyphenols Plants Disease Research Fields Inflammation/Immunology
Target:
Cat. No.: HY-W061674
CAS No.: 13991-37-2
Synonyms: (E)-Pent-2-enoic acid
Cat. No.: HY-N21561
CAS No.: 740838-55-5
Target:
Cat. No.: HY-N18043
CAS No.: 103744-81-6
Category:
Rehmannia glutinosa (Gaertn.) Libosch. ex Fisch. & C. A. Mey. Terpenoids Sesquiterpenes Orobanchaceae Plants Steroids
Target:
Cat. No.: HY-114324A
Purity: 98.99%
rel-PROTAC PARP1 degrader is the relative configuration of ROTAC PARP1 degrader (HY-114324). PROTAC PARP1 degrader is a PROTAC PARP1 degrader. PROTAC PARP1 degrader mediates the interaction between PARP1 and MDM2 E3 ubiquitin ligase, thereby inducing ubiquitination of PARP1 and subsequent proteasome-mediated degradation. PROTAC PARP1 degrader selectively inhibits the growth of breast cancer cells. PROTAC PARP1 degrader induces cell apoptosis by activating caspase-3 and phosphatidylserine externalization. PROTAC PARP1 degrader can be used in the research of triple-negative breast cancer .
Cat. No.: HY-106899A
CAS No.: 143445-03-8
Synonyms: (rel)-L-680573
Research Areas:
(rel)-MK 287 ((rel)-L-680573) is a relative configuration of MK 287. MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
Cat. No.: HY-N11424
CAS No.: 17459-92-6
Category:
Target:
Cat. No.: HY-N21558
CAS No.: 135463-09-1
Category:
Target:
Cat. No.: HY-E71350
Target:
Research Areas:
κ-Carrageenase from Zobellia galactanivorans (EC 3.2.1.83) is an enzyme systematically named κ-carrageenan 4-β-D-glycanohydrolase (configuration-retaining). κ-Carrageenase from Zobellia galactanivorans hydrolyzes κ-carrageenan in an endolytic manner, primarily producing κ-neocarratetraose (DP4) and κ-neocarrahexaose (DP6). κ-Carrageenase, Zobellia galactanivorans generates κ-carrageenan oligosaccharides (κ-COS) that exhibit antioxidant, immunomodulatory, antitumor, anticoagulant, and antiviral activities via Nrf2/NF-κB/AMPK and other pathways; the enzyme itself possesses only catalytic activity and no direct pharmacological effects .
Cat. No.: HY-W756265
Research Areas:
(R)-(-)-N-Boc-3-pyrrolidinol-d4 is the d4-labeled (R)-(-)-N-Boc-3-pyrrolidinol (HY-W001294). (R)-(-)-N-Boc-3-pyrrolidinol is a chiral pyrrolidine derivative. After undergoing configuration inversion via the Mitsunobu reaction, (R)-(-)-N-Boc-3-pyrrolidinol can serve as a precursor for the (3S)-aryloxypyrrolidine fragment, which is used to construct key intermediates of FXa inhibitors (such as DX-9065a (HY-10722)) and various chiral drugs. (R)-(-)-N-Boc-3-pyrrolidinol can be applied in studies related to arrhythmia .
Cat. No.: HY-N13729
CAS No.: 2376309-57-6
Target:
Cat. No.: HY-19205B
CAS No.: 205654-37-1
Research Areas:
(2S,5S)-CMI-392 is the absolute configuration of CMI-392 (HY-19205A). CMI-392 is an orally active dual 5-lipoxygenase inhibitor and platelet-activating factor receptor (PAFR) antagonist, with an IC50 of 10 nM for human PAF receptor and an IC50 of 100 nM for rat 5-lipoxygenase. CMI-392 blocks PAF receptor binding, inhibits leukotriene synthesis, attenuates PAF-induced hemoconcentration, and suppresses arachidonic acid- and TPA-induced ear swelling in mice. CMI-392 reduces inflammatory cell infiltration, decreases MPO levels, alleviates ocular inflammation, and improves dextran sulfate sodium-induced colitis. CMI-392 can be used in the research of inflammatory and immune-related diseases such as colitis and atopic dermatitis .
Cat. No.: HY-P2632
CAS No.: 289042-25-7
Synonyms: RADA16
Target:
Research Areas:
Cat. No.: HY-168895A
CAS No.: 3125025-29-5
Target:
Research Areas:
(E,E)-c-Fos-IN-1 is the active stereoisomer of c-Fos-IN-1 (HY-168895) in which both double bonds are in the trans configuration. c-Fos-IN-1 (Compound P16) is a c-Jun inhibitor, and decreases mRNA levels and protein levels of c-Fos. c-Fos-IN-1 also inhibits the phosphorylation activity of ERK and the transcriptional activity of AP-1. c-Fos-IN-1 shows anticancer activity by inhibiting ERK/c-Fos/Jun pathway. c-Fos-IN-1 inhibits the proliferation and migration of gastric cancer cells (IC50: 2.31 μM for MGC-803 cell). c-Fos-IN-1 arrests cell cycle at G2/M phase and induces cancer cell apoptosis. c-Fos-IN-1 inhibits gastric cancer tumor growth .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
